Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

被引：0
|
作者：
Timothy Wigal
Matthew Brams
Maria Gasior
Joseph Gao
Liza Squires
John Giblin
机构：
[1] Irvine,Department of Pediatrics, University of California
[2] Child Development Center,Private Practice
[3] Bayou City Research,Global Clinical Medicine
[4] Shire Development Inc.,undefined
[5] Biostats,undefined
[6] Shire Development Inc.,undefined
[7] Clinical Study Centers,undefined
[8] LLC,undefined
来源：
Behavioral and Brain Functions | / 6卷
关键词：
ADHD Symptom; Lisdexamfetamine; Clinical Global Impression; Crossover Phase; Lisdexamfetamine Dimesylate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 38 条
  • [11] Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
    David R. Coghill
    Tobias Banaschewski
    Michel Lecendreux
    Alessandro Zuddas
    Ralf W. Dittmann
    Isabel Hernández Otero
    Richard Civil
    Ralph Bloomfield
    Liza A. Squires
    European Child & Adolescent Psychiatry, 2014, 23 : 61 - 68
  • [12] Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial
    Coghill, David R.
    Banaschewski, Tobias
    Lecendreux, Michel
    Zuddas, Alessandro
    Dittmann, Ralf W.
    Otero, Isabel Hernandez
    Civil, Richard
    Bloomfield, Ralph
    Squires, Liza A.
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2014, 23 (02) : 61 - 68
  • [13] The Efficacy and Safety Profile of Lisdexamfetamine Dimesylate, a Prodrug of d-Amphetamine, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adults
    Najib, Jadwiga
    CLINICAL THERAPEUTICS, 2009, 31 (01) : 142 - 176
  • [14] Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses
    Martin, Patrick
    Dirks, Bryan
    Gertsik, Lev
    Walling, David
    Stevenson, Annette
    Corcoran, Mary
    Raychaudhuri, Aparna
    Ermer, James
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (06) : 682 - 689
  • [15] Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial
    Coghill, David R.
    Banaschewski, Tobias
    Lecendreux, Michel
    Soutullo, Cesar
    Zuddas, Alessandro
    Adeyi, Ben
    Sorooshian, Shaw
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 2039 - 2047
  • [16] Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults
    Ermer, James
    Haffey, Mary B.
    Richards, Cynthia
    Lasseter, Kenneth
    Adeyi, Ben
    Corcoran, Mary
    Stanton, Beverly
    Martin, Patrick
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 219 - 229
  • [17] A head-to-head, double-blind, randomized, phase 3b trial comparing the efficacy of lisdexamfetamine dimesylate with atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder
    Dittmann, Ralf
    Cardo, Esther
    Coghill, David
    Nagy, Peter
    Adeyi, Ben
    Anderson, Colleen
    Caballero, Beatriz
    Higgins, Nicholas
    Hodgkins, Paul
    Civil, Richard
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2013, 22 : S222 - S223
  • [18] A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
    Wigal, Tim L.
    Newcorn, Jeffrey H.
    Handal, Nelson
    Wigal, Sharon B.
    Mulligan, Ioulietta
    Schmith, Virginia
    Konofal, Eric
    CNS DRUGS, 2018, 32 (03) : 289 - 301
  • [19] A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy
    Richards, Cynthia
    Iosifescu, Dan, V
    Mago, Rajnish
    Sarkis, Elias
    Reynolds, James
    Geibel, Brooke
    Dauphin, Matthew
    JOURNAL OF PSYCHOPHARMACOLOGY, 2017, 31 (09) : 1190 - 1203
  • [20] Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study
    Biederman, Joseph
    Krishnan, Suma
    Zhang, Yuxin
    McGough, James J.
    Findling, Robert L.
    CLINICAL THERAPEUTICS, 2007, 29 (03) : 450 - 463
1234